Who are bitopertin [RO4917838] level 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avodart, Efrane, Methohexitone, Nux vomica (active comparator), tetrahydrocannabinol, sevorane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bitopertin-ro4917838-level-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

bitopertin [RO4917838] level 2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bitopertin [RO4917838] level 2 (bitopertin [RO4917838] level 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycine receptor antagonist. Area: Psychiatry.

phase 3 Glycine receptor antagonist Glycine receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

bitopertin [RO4917838] level 2 (bitopertin [RO4917838] level 2) — Hoffmann-La Roche. Bitopertin is a glycine receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bitopertin [RO4917838] level 2 TARGET	bitopertin [RO4917838] level 2	Hoffmann-La Roche	phase 3	Glycine receptor antagonist	Glycine receptor
Avodart	dutasteride	GSK (GlaxoSmithKline)	marketed	5-alpha-reductase inhibitor (dual)	3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1	2001-11-20
Efrane	ENFLURANE	Baxter	marketed	General Anesthetic	Glycine receptor subunit alpha-1	1972-01-01
Methohexitone	Methohexitone	St Patrick's Hospital, Ireland	marketed		Neuronal acetylcholine receptor; alpha2/beta2, Glycine receptor subunit alpha-1, GABA-A receptor alpha-1/beta-3/gamma-2
Nux vomica (active comparator)	Nux vomica (active comparator)	Medical University of Vienna	marketed	Herbal alkaloid preparation	Glycine receptor (competitive antagonist)
tetrahydrocannabinol	tetrahydrocannabinol	Wageningen University	marketed		N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1
sevorane	sevorane	University Hospital, Ghent	marketed		Glycine receptor subunit alpha-1, Potassium channel subfamily K member 10, Potassium channel subfamily K member 18

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycine receptor antagonist class)

Hoffmann-La Roche · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bitopertin [RO4917838] level 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/bitopertin-ro4917838-level-2. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing